3β-HSD (3β-Hydroxysteroid Dehydrogenase) is a key enzyme in the steroid hormone biosynthesis pathway, catalyzing the conversion of precursors such as pregnenolone and dehydroepiandrosterone (DHEA) into progesterone and androstenedione, which are further used to synthesize glucocorticoids, mineralocorticoids, androgens, and estrogens.
3β-HSD exists in multiple isoforms in both humans and mice. In humans, the main isoforms are HSD3B1 (placenta, skin, mammary gland) and HSD3B2 (adrenal glands, gonads), with HSD3B2 being essential for the biosynthesis of glucocorticoids, mineralocorticoids, and sex hormones. In mice, 3β-HSD I is predominantly expressed in the adrenal glands and gonads, playing a key role in steroidogenesis, whereas 3β-HSD VI is expressed in the decidua and trophoblast cells during early pregnancy, regulating progesterone synthesis and potentially supporting embryo survival through immune suppression.
3β-HSD plays a crucial role in steroid biosynthesis, placental function, sex hormone metabolism, and endocrine disorders. HSD3B2 mutations can cause congenital 3β-HSD deficiency, leading to adrenal insufficiency, abnormal sexual development, and electrolyte imbalance. Dysregulation of HSD3B1 and HSD3B2 activity can result in androgen excess, contributing to polycystic ovary syndrome (PCOS). Moreover, HSD3B1 dysfunction has been implicated in recurrent early pregnancy loss, while 3β-HSD V, primarily expressed in the male liver, may promote the progression of androgen-dependent prostate cancer when aberrantly expressed[1].
3βHSD1-IN-1(Compound 46)是一种3β-羟类固醇脱氢酶1(3βHSD1)抑制剂,IC50为55 nM,能有效抑制雄激素受体活性,可用于前列腺癌等疾病的研究。
Epostane (WIN 32729) 是一种口服有效的 3β-hydroxysteroid dehydrogenase 抑制剂,IC50 为 1.45 nM,可抑制大鼠排卵和妊娠。
HEAL-116 是一种强效、特异性且具有口服活性的 1 型 3β-羟类固醇脱氢酶 (3βHSD1) 抑制剂,IC50 值为 1.18 μM,KD 值为 1.32 μM,可抑制 DHEA (MS-U58696) 的代谢以及 DHEA 诱导的靶基因表达和细胞增殖,可用于癌症研究,如前列腺癌。
Trilostane-15N,d3 (Win 24540-15N,d3) 是氘代标记的 Trilostane (MS-O17974),而 Trilostane (Win 24540) 是一种竞争性的、具有口服活性的 3-β-羟基甾体脱氢酶 (3β-HSD) 抑制剂,也是一种合成的非激素类固醇,可用于乳腺癌和前列腺癌的研究。
Trilostane (Win 24540) 是一种竞争性的、具有口服活性的 3-β-羟基甾体脱氢酶 (3β-HSD) 抑制剂,也是一种合成的非激素类固醇,可用于乳腺癌和前列腺癌的研究。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号